These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37406085)

  • 1. Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.
    Flint AC; Mitchell DK; Angus SP; Smith AE; Bessler W; Jiang L; Mang H; Li X; Lu Q; Rodriguez B; Sandusky GE; Masters AR; Zhang C; Dang P; Koenig J; Johnson GL; Shen W; Liu J; Aggarwal A; Donoho GP; Willard MD; Bhagwat SV; Clapp DW; Rhodes SD
    Clin Cancer Res; 2023 Sep; 29(17):3438-3456. PubMed ID: 37406085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
    Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
    Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status of MEK inhibitors in the treatment of plexiform neurofibromas.
    Gross AM; Dombi E; Widemann BC
    Childs Nerv Syst; 2020 Oct; 36(10):2443-2452. PubMed ID: 32607696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
    Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
    Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.
    Liu JL; You YH; Tian ZW; Xiao M; Zheng JW; Wang YA; Du Z
    Int J Med Sci; 2021; 18(9):2008-2016. PubMed ID: 33850471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
    Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
    J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.
    Ferguson MJ; Rhodes SD; Jiang L; Li X; Yuan J; Yang X; Zhang S; Vakili ST; Territo P; Hutchins G; Yang FC; Ingram DA; Clapp DW; Chen S
    Pediatr Blood Cancer; 2016 Feb; 63(2):206-13. PubMed ID: 26375012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of YAP Sensitizes the Selumetinib Treatment for Neurofibromatosis Type 1 Related Plexiform Neurofibroma.
    Tian Z; You Y; Xiao M; Liu J; Xu G; Ma C; Du Z; Wang Y
    Int J Med Sci; 2023; 20(1):125-135. PubMed ID: 36619222
    [No Abstract]   [Full Text] [Related]  

  • 9. Combined Cyclin-Dependent Kinase Inhibition Overcomes MAPK/Extracellular Signal-Regulated Kinase Kinase Inhibitor Resistance in Plexiform Neurofibroma of Neurofibromatosis Type I.
    Wang W; Cui XW; Gu YH; Wei CJ; Li YH; Ren JY; Chung MH; Aimaier RH; Zhang HB; Li QF; Wang ZC
    J Invest Dermatol; 2022 Mar; 142(3 Pt A):613-623.e7. PubMed ID: 34534577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining SOS1 and MEK Inhibitors in a Murine Model of Plexiform Neurofibroma Results in Tumor Shrinkage.
    Jackson M; Ahmari N; Wu J; Rizvi TA; Fugate E; Kim MO; Dombi E; Arnhof H; Boehmelt G; Düchs MJ; Long CJ; Maier U; Trapani F; Hofmann MH; Ratner N
    J Pharmacol Exp Ther; 2023 May; 385(2):106-116. PubMed ID: 36849412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.
    Mitchell DK; Burgess B; White EE; Smith AE; Sierra Potchanant EA; Mang H; Hickey BE; Lu Q; Qian S; Bessler W; Li X; Jiang L; Brewster K; Temm C; Horvai A; Albright EA; Fishel ML; Pratilas CA; Angus SP; Clapp DW; Rhodes SD
    Clin Cancer Res; 2024 Mar; 30(5):1038-1053. PubMed ID: 38127282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions.
    Mußotter T; Kluwe L; Högel J; Nguyen R; Cooper DN; Mautner VF; Kehrer-Sawatzki H
    BMC Med Genet; 2012 Oct; 13():98. PubMed ID: 23101500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
    Gottfried ON; Viskochil DH; Couldwell WT
    Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications.
    Marjanska A; Galazka P; Wysocki M; Styczynski J
    Anticancer Res; 2020 Apr; 40(4):1817-1831. PubMed ID: 32234870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of
    Burks CA; Rhodes SD; Bessler WK; Chen S; Smith A; Gehlhausen JR; Hawley ET; Jiang L; Li X; Yuan J; Lu Q; Jacobsen M; Sandusky GE; Jones DR; Clapp DW; Blakeley JO
    Mol Cancer Ther; 2019 Dec; 18(12):2321-2330. PubMed ID: 31527226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
    Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
    Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant variants in NF1, LZTR1 and GNAZ genes probably contribute to the aggressiveness of plexiform neurofibroma and warrant treatment with MEK inhibitor.
    Cohen-Barak E; Toledano-Alhadef H; Danial-Farran N; Livneh I; Mwassi B; Hriesh M; Zagairy F; Gafni-Amsalem C; Bashir H; Khayat M; Warrour N; Sher O; Marom D; Postovsky S; Dujovny T; Ziv M; Shalev SA
    Exp Dermatol; 2022 May; 31(5):775-780. PubMed ID: 34913528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A molecular basis for neurofibroma-associated skeletal manifestations in NF1.
    Ma Y; Gross AM; Dombi E; Pemov A; Choi K; Chaney K; Rhodes SD; Angus SP; Sciaky N; Clapp DW; Ratner N; Widemann BC; Rios JJ; Elefteriou F
    Genet Med; 2020 Nov; 22(11):1786-1793. PubMed ID: 32601387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
    Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
    Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling tumors of the peripheral nervous system associated with Neurofibromatosis type 1: Reprogramming plexiform neurofibroma cells.
    Mazuelas H; Carrió M; Serra E
    Stem Cell Res; 2020 Dec; 49():102068. PubMed ID: 33160273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.